Ameriprise’s Trillium Therapeutics Inc. TRIL Stock Holding History

Ameriprise’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,062	Closed	-$405K	–	4109
2021 Q3	$405K	Buy	+23,062	New	+$269K	﹤0.01%	3471

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Ameriprise's TRIL Position: Q4 2021 in Review

Ameriprise sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 23,062 shares — an estimated $405K sold.

Ameriprise first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $405K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Ameriprise reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Ameriprise sold 23,062 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $405K.
Ameriprise first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Ameriprise's Trillium Therapeutics Inc. position peaked at $405K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Ameriprise's 13F filing for Q4 2021, filed 14 Feb 2022.